insights_auto
Why is AGIO up 4,99%?
Dive Deeperchevron_right
AGIO:NASDAQ
Agios Pharmaceuticals Inc
36,64 $
arrow_upward
+4,99%(+1,74) 1D
36,64 $
0,00% (0,00)
bedtimeAfter hours
Closed: 20 հոկ, 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Open
35,04 $
High
37,00 $
Low
35,02 $
Mkt. cap
2,19 մլրդ
Avg. vol.
1,14 մլն
Volume
31,00
52-wk high
45,99 $
52-wk low
22,24 $
EPS
-7,01 $
Beta
0,63
Shares outstanding
59,70 մլն
No. of employees
540
Open
35,04 $
High
37,00 $
Low
35,02 $
Mkt. cap
2,19 մլրդ
Avg. vol.
1,14 մլն
Volume
31,00
52-wk high
45,99 $
52-wk low
22,24 $
EPS
-7,01 $
Beta
0,63
Shares outstanding
59,70 մլն
No. of employees
540
News stories
From web sources and news partners
Yahoo Finance
·
10 ժամ առաջ
Did Priority Review Just Shift Agios Pharmaceuticals' (AGIO) Investment Narrative?
Stock Traders Daily
·
14 ժամ առաջ
(AGIO) Price Dynamics and Execution-Aware Positioning
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc